1-3 of 3
Liat Flaishon, PhD MD
Close
Save search
Sort by
Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Free
Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-139136
Published: 2020
Journal Articles

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

Free
Shoshi Tessler, PhD, Inbal Mishalian, PhD, Ronny Peri-Naor, PhD, Stela Gengrinovitch, PhD, Raphael Mayer, PhD, Ruth Ben Yakar, PhD, Amnon Peled, Liat Flaishon, PhD MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1451.
https://doi.org/10.1182/blood-2018-99-112092
Published: 2018
Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Free
Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 893.
https://doi.org/10.1182/blood.V130.Suppl_1.893.893
Published: 2017